

# Improving STING Agonist Delivery for Cancer Immunotherapy Using Biodegradable Mesoporous Silica Nanoparticles

Kyung Soo Park, Cheng Xu, Xiaoqi Sun, Cameron Louttit, and James J. Moon\*

Stimulator of interferon genes (STING) activation by intratumoral STING agonist treatment has been recently shown to eradicate tumors in preclinical models of cancer immunotherapy, generating intense research interest and leading to multiple clinical trials. However, there are many challenges associated with STING agonist-based cancer immunotherapy, including low cellular uptake of STING agonists. Here, biodegradable mesoporous silica nanoparticles (bMSN) with an average size of 80 nm are developed for efficient cellular delivery of STING agonists. STING agonists delivered via bMSN potently activate innate and adaptive immune cells, leading to strong antitumor efficacy and prolonged animal survival in murine models of melanoma. Delivery of immunotherapeutic agents via biodegradable bMSN is a promising approach for improving cancer immunotherapy.

Stimulator of interferon genes (STING) molecule is one of the pattern recognition receptor proteins that detect intracellular DNA. It serves to protect the host against intracellular invasions by pathogens, such as virus and bacteria. Foreign DNA is detected by cyclic GMP-AMP (cGAMP) synthase (cGAS), which produces cGAMP from adenosine triphosphate (ATP) and guanosine triphosphate (GTP), leading to subsequent activation of STING. The cGAS-STING pathway activates a cascade of immune pathways, including IRF3 and nuclear factor kappa-light-chain-enhancer of activated B cells (NF- $\kappa$ B), resulting in potent type I interferon (IFN) response.<sup>[1]</sup> Importantly, a number of recent studies revealed that STING plays a crucial role in sensing spontaneously arising tumors and initiating innate immune responses.<sup>[2]</sup> Numerous studies have reported promising anticancer effects of STING agonists,<sup>[3,4]</sup>

including preclinical studies that have shown STING agonist-mediated tumor regression and durable antitumor immunity.<sup>[5,6]</sup> Thus, STING has sparked intense research interest in the field of cancer immunotherapy<sup>[7,8]</sup> and there are multiple clinical trials underway to evaluate the therapeutic efficacy of STING agonists.

However, there are major challenges associated with STING activators for cancer immunotherapy. As STING agonists are based on cyclic dinucleotides with negative charges, their cellular permeability is minimal. Due to their small molecular weight, STING agonists diffuse rapidly into systemic circulation upon injection, limiting drug exposure in tumor tissues and

potentially causing off-target toxicities. In addition, the amount of STING agonist injected to tumor has been shown to dictate CD8+ T cell response,<sup>[9]</sup> underscoring the importance of regulating the dose and pharmacokinetics of STING agonist to achieve robust antitumor immunity. To address these issues, various nanoparticles (NPs) carrying STING agonists and polymers with STING-activating properties have been developed with varying degrees of success reported in preclinical models.<sup>[10–14]</sup> Here, we sought to promote cellular delivery of STING agonists using a well-established NP system with a strong track record of biocompatibility, safety, and manufacturability. In particular, mesoporous silica nanoparticle (MSN) is a widely used inorganic drug delivery nanocarrier with tunable size, low immunogenicity, controlled release of cargo materials, and facile and low-cost preparation process.<sup>[15,16]</sup> However, while synthetic MSNs composed of amorphous silica are generally considered to be biocompatible, their limitations include relatively small pore sizes for drug loading, slow biodegradation, and long-term tissue retention.<sup>[17–21]</sup>

To address these issues, we have developed biodegradable mesoporous silica nanoparticles (bMSN) for cytosolic delivery of STING agonists (**Figure 1**). We have recently shown that bMSN with a less-dense Si—O—Si matrix undergoes faster biodegradation process than conventional MSN and that bMSN's large pore size ranging 5–10 nm allows for efficient loading and delivery of biomacromolecules for combination cancer treatments.<sup>[22]</sup> Here, we report that bMSN surface-modified with amine serves as a promising platform for cellular delivery of STING agonists and immune activation. Using two murine models of melanoma, we demonstrate the therapeutic efficacy of bMSN carrying STING agonists, highlighting the potential of bMSN for applications in cancer immunotherapy.


K. S. Park, Dr. C. Louttit, Prof. J. J. Moon  
Department of Biomedical Engineering  
University of Michigan  
Ann Arbor, MI 48109, USA  
E-mail: moonjj@med.umich.edu

K. S. Park, Dr. C. Xu, X. Sun, Dr. C. Louttit, Prof. J. J. Moon  
Biointerfaces Institute  
University of Michigan  
Ann Arbor MI 48109, USA

Dr. C. Xu, X. Sun, Prof. J. J. Moon  
Department of Pharmaceutical Sciences  
University of Michigan  
Ann Arbor MI 48109, USA

 The ORCID identification number(s) for the author(s) of this article can be found under <https://doi.org/10.1002/adtp.202000130>

DOI: 10.1002/adtp.202000130



**Figure 1.** Schematic illustration of bMSN for delivery of STING agonists.


We synthesized bMSN as we previously reported with some modifications for cytosolic delivery of STING agonists.<sup>[22]</sup> The resulting bMSN had an approximate average diameter of 80 nm, as visualized by transmission electron microscopy (TEM) (Figure 2a). Compared with conventional mesoporous silica nanoparticles, bMSN had a larger pore size (5–10 nm) and a thinner Si–O–Si matrix that allowed for rapid degradation within 120 h in a physiological condition (Figure 2b). We loaded bMSN with a model STING agonist, bis-(3'-5')-cyclic dimeric adenosine monophosphate (CDA). Since CDA is a dicyclic nucleotide with anionic charges, the silica surface of bMSN was modified with amines (–NH<sub>2</sub>) to facilitate charge-mediated drug loading. The amine-modification changed the zeta potential of bMSN from –27.6 to 9.3 mV but did not affect the size of the nanoparticles (Figure 2c,d). The resulting bMSN-NH<sub>2</sub> (henceforth referred to as bMSN) was incubated at various concentrations with a fixed amount of CDA (8 μg). After CDA was simply mixed and incubated with preformed bMSN for 1 h, we observed >90% loading of 8 μg CDA into 25 μg of bMSN (Figure 2e), indicating drug loading of ≈290 μg mg<sup>-1</sup> of bMSN (CDA@bMSN). CDA was released from CDA@bMSN within 1 h at pH 7.0 (Figure 2f). However, when incubated at a slightly acidic condition of pH 6.0 mimicking the conditions within the tumor microenvironment (TME),<sup>[23]</sup> we observed slower release of CDA (Figure 2f).

Next, we examined cellular uptake of CDA@bMSN using mouse bone marrow-derived dendritic cells (BMDCs), as a widely used surrogate for APCs. BMDCs incubated with free fluorophore-tagged CDA for 6 h showed a minimal increase in the fluorescence signal (Figure 2g), whereas BMDCs incubated with CDA@bMSN exhibited markedly enhanced CDA signal (Figure 2g). Similarly, confocal microscopy revealed that BMDCs and B16F10 melanoma cells incubated with fluorophore-tagged CDA@bMSN exhibited much stronger cytosolic fluorescence signal, compared with minimal signal in cells treated with free CDA (Figure 2h and Figure S1, Supporting Information), demonstrating efficient bMSN-mediated cytosolic delivery of STING agonist.


In addition, CDA@bMSN treatment led to robust BMDC activation, as evidenced by significantly increased expression of CD40 ( $P < 0.0001$ ) and CD86 ( $P < 0.001$ ), compared with free CDA treatment (Figure 2i), likely due to the increased cellular uptake of CDA@bMSN. Blank bMSN slightly increased the expression level of CD40, but not CD86, indicating minimal immune activation by the blank bMSN itself. Next, we used THP1-Blue interferon-stimulated genes (ISG) (human monocyte-derived cells expressing a reporter gene for STING activation) to study the effects of CDA@bMSN on STING activation. Compared with free CDA, CDA@bMSN induced significantly stronger STING activation even at 12.5 μg mL<sup>-1</sup> dose of CDA ( $P < 0.0001$ , Figure 2j), indicating amplification STING activation by bMSN-mediated delivery of CDA. Notably, both THP1-Blue ISG cells and primary CD8+ T cells incubated with either free CDA or CDA@bMSN exhibited similar levels of viability (Figures S2 and S3, Supporting Information), showing biocompatibility of CDA@bMSN. We have also previously reported biological safety of the bMSN platform.<sup>[22]</sup> Taken together, compared with free soluble CDA, CDA@bMSN significantly improved cellular uptake of CDA and amplified STING activation, without negatively affecting cytotoxicity.

We examined secretion of cytokines and chemokines from BMDCs treated with CDA formulations. In line with the enhanced uptake of CDA and activation of BMDCs (Figure 2g–j), CDA@bMSN treatment significantly increased the release of interleukin-6 (IL-6), IL-12p40, IFN-β, CXCL10, CCL2, CCL3, and CCL5 from BMDCs, compared with free CDA ( $P < 0.0001$ , Figure 3a). Although tumor-infiltrating immune cells are known as the major cell types that are activated by STING agonists and initiate antitumor immune response, tumor cells also have been shown to respond to STING agonists.<sup>[24,25]</sup> We examined whether CDA treatment can promote cytokine and chemokine production from melanoma cell lines, B16F10 and B16F10OVA. Tumor cells incubated with free CDA did not release any detectable levels of cytokines or chemokines; however, CDA@bMSN treatment led to significantly amplified secretion of CXCL10 and CCL5 from B16F10 cells and CCL2 and CCL5 from B16F10OVA cells ( $P < 0.01$  for CCL2 and  $P < 0.0001$  for the others, Figure 3b). In order to confirm STING-dependent activation, we pretreated BMDCs with an STING inhibitor, C-178, followed by incubation with CDA formulations. Pretreatment with C-178 significantly decreased the secretion of cytokines and chemokines induced by both free CDA and CDA@bMSN (Figure 3c), showing that CDA-mediated immune activation is indeed dependent on the STING pathway.

Next, antitumor effects of CDA@bMSN was investigated in a murine melanoma model of B16F10OVA. C57BL/6 mice were injected subcutaneously with  $3 \times 10^5$  B16F10OVA cells on the right-side flank. When tumors reached >100 mm<sup>3</sup> on day 6 after tumor inoculation, we performed a single intratumoral administration of 2 μg CDA in either bMSN or free form (Figure 4a). Interestingly, both free CDA and CDA@bMSN treatments were able to induce regression of established tumors with minimal tumor volume by day 14 (Figure 4b). However, 50% of mice in the free CDA-treated group quickly relapsed and had to be euthanized by day 30. In stark contrast, 100% mice in the CDA@bMSN treatment group remained tumor free for the duration of the study (Figure 4c). To understand the differences between the free CDA



**Figure 2.** Cellular delivery of STING agonists using bMSN. a) TEM image of bMSN. b) Degradation of bMSN in a physiological condition (Krebs–Henseleit solution at 37 °C). c) Surface charge and d) hydrodynamic size of bMSN measured before and after amine-modification using dynamic light scattering (DLS). Particles were transferred to water for measurements. e) CDA-loading capacity of bMSN. f) CDA Release profiles in different pH conditions. g,h) Uptake of CDA by BMDCs assessed in vitro with g) flow cytometry and h) confocal microscopy. i) Activation of BMDCs measured by flow cytometry after 4 h of incubation. j) STING activation of human monocyte-derived THP1-Blue ISG cells measured after overnight incubation. All data are presented as mean ± SEM, showing representative results from two independent studies with  $n = 3$ , with an exception of g) with  $n = 1$ . Scale bars in a,b) = 100 nm and h) = 5 μm. \*\* $P < 0.01$ , \*\*\* $P < 0.001$ , \*\*\*\* $P < 0.0001$  analyzed by one-way or two-way ANOVA with Tukey's honestly significant difference (HSD) multiple comparison post hoc test.




**Figure 3.** CDA@bMSN promotes cytokine and chemokine release from BMDCs and tumor cells. a) Mouse BMDCs and b) mouse melanoma cell lines, B16F10 and B16F10OVA, were treated with  $10 \mu\text{g mL}^{-1}$  of CDA for 6 h in vitro. Supernatants were assessed by enzyme-linked immunosorbent assay (ELISA) for cytokines and chemokines. c) BMDCs pretreated for 1 h with  $0.5 \times 10^{-6} \text{ M}$  of an STING inhibitor, C-178, followed by treatment with  $10 \mu\text{g mL}^{-1}$  of CDA for 6 h. Data are presented as mean  $\pm$  SEM, showing representative results from two independent studies with  $n = 3\text{--}4$ . \*\* $P < 0.01$ , \*\*\* $P < 0.001$ , \*\*\*\* $P < 0.0001$  analyzed by one-way or two-way ANOVA with Tukey's HSD multiple comparison post hoc test.

and CDA@bMSN treatment groups, we analyzed the levels of cytokines and chemokines as well as various immune cell subsets. In line with our in vitro results (Figure 3), after 3 h of intratumoral administration, CDA@bMSN induced strong release of IFN- $\beta$ , CXCL10, CCL2, and CCL5 in TME and serum (Figure 4d,e). Notably, even after 24 h of administration, higher levels of CXCL10 and CCL2 were detected within the TME for the CDA@bMSN group, compared with free CDA group ( $P < 0.05$ , Figure 4d), suggesting sustained immune activation mediated by bMSN.

We also investigated the effects of CDA treatment on the innate and adaptive immune responses. Intratumoral administration of CDA@bMSN led to robust activation of DCs within the TME, as evidenced by upregulation of CD86 within 3 h and CD40 within 24 h post-treatment (Figure 4f). There was a trend for higher ex-

pression levels of CD86 and CD40 on DCs after 24 h of treatment with CDA@bMSN, compared with free CDA (Figure 4f) although their differences were not statistically significant. While free CDA treatment induced transient upregulation and downregulation of CD107 $\alpha$ , a degranulation marker, on intratumoral natural killer (NK) cells, CDA@bMSN treatment led to sustained expression of CD107 $\alpha$  on intratumoral NK cells for up to 24 h ( $P < 0.5$ , Figure 4g). By 24 h of CDA@bMSN treatment, we also observed activation of NK cells in the circulation, as shown by increased levels of CD107 $\alpha$  and NKG2D<sup>[26,27]</sup> (Figure S4, Supporting Information).

Intratumoral injection of free CDA significantly decreased the number of CD8+ T cells within the tumor by 24 h post-CDA injection, compared with no treatment group ( $P < 0.05$ , Figure 4h). This is in line with the literature reporting de-



**Figure 4.** A single intratumoral treatment with CDA@bMSN exerts potent antitumor efficacy. a) C57BL/6 mice were subcutaneously injected with  $3 \times 10^5$  B16F10OVA cells on the right-side flank. After 6 d, each mouse received intratumoral injection of 2 μg CDA as a soluble or bMSN formulations. After 3 or 24 h, blood sampling and tumor excision were performed. b) Tumor growth curves and c) animal survival are shown. d) Cytokine levels within tumor tissues or e) sera were measured by ELISA after 3 and 24 h or 3 h of CDA injection, respectively. Flow cytometric analyses were performed to examine f) CD86 and CD40 expression on DCs, g) CD107α expression on NK cells, and h) the number of CD8+ T cells within the B16F10OVA TME. i) C57BL/6 mice were subcutaneously injected with  $3 \times 10^5$  B16F10 cells on the right-side flank. After 6 d, each mouse received intratumoral injection of 5 μg free CDA or CDA@bMSN. j) Tumor growth curves and k) animal survival curves are shown. Data are presented as mean ± SEM, showing representative results from two independent studies with  $n = 3-4$  for (b) and (c) and  $n = 5$  for (d)–(f).  $n = 15$  for (j) and (k) pooled from two independent studies. \* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$ , \*\*\*\* $P < 0.0001$  analyzed by one-way or two-way ANOVA with Tukey's HSD multiple comparison post hoc test. Animal survival curves were analyzed by the log-rank (Mantel–Cox) test.

creased tumor-infiltration of lymphocytes after intratumoral administration of free STING agonist.<sup>[9,24]</sup> In contrast, intratumoral CDA@bMSN treatment resulted in significantly higher number of intratumoral CD8+ T cells at 24 h time point, compared with free CDA ( $P < 0.01$ , Figure 4h), suggesting that bMSN-mediated CDA delivery reversed the decrease in intratumoral infiltration of CD8+ T cells associated with free CDA.<sup>[9,24]</sup> CDA@bMSN treatment also significantly increased the expression of a degranulation marker, CD107 $\alpha$ , on intratumoral CD8+ T cells by 24 h, compared with untreated control ( $P < 0.05$ , Figure S5, Supporting Information). Overall, these results suggest that bMSN-mediated delivery of CDA amplifies the magnitude and duration of cytokine and chemokine release within TME and potentially activates intratumoral DCs, NK cells, and CD8+ T cells, thus leading to regression of established tumors.

Having observed strong antitumor efficacy of CDA@bMSN, we evaluated CDA@bMSN in the setting of established B16F10 melanoma. As B16F10 is a poorly immunogenic, highly aggressive tumor model, we increased the dose of CDA@bMSN to 5  $\mu\text{g}$ . C57BL/6 mice were inoculated subcutaneously (s.c.) with  $3 \times 10^5$  B16F10 cells. When tumors were  $>50 \text{ mm}^3$  on day 6, we performed a single intratumoral administration of CDA either in a soluble or bMSN forms (Figure 4i). Whereas mice in the untreated control group quickly succumbed to B16F10 tumor with a median survival of 12 d, free CDA treatment slowed the B16F10 tumor growth and extended the median survival to 18 d ( $P < 0.01$ , Figure 4j,k). Compared with free CDA group, CDA@bMSN treatment further inhibited B16F10 tumor growth ( $P < 0.01$ , Figure 4j) and extended the median survival to 24 d ( $P < 0.05$ , Figure 4k), thus highlighting the therapeutic potential of CDA@bMSN.

In summary, we have developed bMSN for efficient cytosolic delivery of STING agonists. While previous studies have reported various STING agonist-loaded NP systems,<sup>[10,11,28–30]</sup> including liposomes and polymeric NPs, their fabrication and drug loading procedures are often complicated with multiple synthesis and separation steps, and many of these NP platforms have not been clinically tested. On the other hand, silica-based NPs offer a promising platform with biocompatibility, facile manufacturing process, and clinical safety.<sup>[15,16,31]</sup> Notably, we have achieved  $>90\%$  loading of CDA into bMSN simply by admixing CDA with preformed bMSN for 1 h. We show that bMSN carrying STING agonists improves STING activation by DCs and tumor cells and elicits potent innate and adaptive immune responses in vivo, leading to strong antitumor efficacy and prolonged animal survival in murine models of melanoma. While the mechanisms underlying bMSN-mediated STING activation and subsequent cascades of innate and adaptive immune responses remain to be elucidated, our results suggest that bMSN is a biodegradable and biocompatible carrier for efficient delivery of STING agonists. It is also notable that the typical dose of STING agonists reported in the literature ranges from 10 to 240  $\mu\text{g}$ , often used in combination with chemotherapeutic or immunotherapeutic agents.<sup>[5,9,32–36]</sup> In contrast, we report that a single injection of CDA@bMSN at the dose of 5  $\mu\text{g}$  or less exerted potent antitumor efficacy, thus highlighting the dose-sparing effect of the bMSN platform. Recent advances in cancer immunotherapy have generated intense research interest in drug delivery vehicles for improving immune activation,<sup>[37–40]</sup> and our bMSN system may

offer a promising platform for delivery of immunomodulatory agents for cancer immunotherapy. Nevertheless, as our current studies have mainly focused on the acute responses mounted by innate immune cells after intratumoral CDA injection, our future studies will address the effects of bMSN-based CDA delivery on adaptive immune responses and examine systemic delivery of CDA@bMSN. Further research is warranted to optimize the bMSN platform for the delivery of STING agonists in the context of combination cancer immunotherapy.

## Experimental Section

**Synthesis of bMSN and CDA Loading:** bMSN was synthesized by an oil–water biphasic reaction approach.<sup>[22,41]</sup> Twenty-four milliliters of (25 wt%) cetyltrimethylammonium chloride (CTAC) solution and 0.18 g of triethylamine (TEA) were added to 36 mL of water and stirred gently at 60 °C for 1 h. Twenty milliliters of tetraethyl orthosilicate (TEOS) in cyclohexane (10% v/v) was carefully added to 60 mL of the water–CTAC–TEA solution (0.3 M CTAC and  $20 \times 10^{-3}$  M TEA) and kept at 60 °C. The reaction was kept at a constant temperature with continuous stirring for 18 h to obtain nanoparticles. They were washed with ethanol for three times and water for two times with centrifugation at  $15\,500 \times g$  for 15 min. Surfactant was removed by incubating the nanoparticles in 10%  $\text{NH}_4\text{NO}_3$ /ethanol v/v at 50 °C overnight, followed by washing. The resulting nanoparticles were freeze dried and stored at 4 °C until use. To load CDA, 40  $\mu\text{g}$  of CDA was mixed with 225  $\mu\text{g}$  of bMSN in  $5 \times 10^{-3}$  M histidine buffer, followed by 1 min of bath sonication. The mixture was incubated in 37 °C for 1 h under constant shaking, then centrifuged at  $10\,000 \times g$  for 5 min. After removing the supernatant, the pellet was dispersed into phosphate buffered saline (PBS). The resulting CDA@bMSN showed 96.3% of CDA loading efficiency.

**In Vivo Studies:** Animals were cared for following the federal, state, and local guidelines. The University of Michigan, Ann Arbor is an Assessment and Accreditation of Laboratory Animal Care (AAALAC) international accredited institution and all work conducted on animals was in accordance with and approved by the Institutional Animal Care and Use Committee (IACUC) with the protocol # PRO00008587. Female C57BL/6 mice, 5–6 weeks in age (the Jackson Laboratory) were inoculated subcutaneously with  $3 \times 10^5$  mouse melanoma cells (either B16F10 or B16F10OVA) on the right-side flank. After 6 d, mice received CDA formulations (PBS as control) via intratumoral injection. Blood sampling and tumor excision were performed on the indicated time points. Blood samples were collected from the facial vein using a lancet. In a separate study, tumor sizes were measured every 2–3 d for monitoring tumor growth.

**Statistical Analysis:** Data are presented as mean  $\pm$  standard error of the mean (SEM). Data were approximately normally distributed, and variance was similar between the groups. Experiments were repeated multiple times as independent experiments with the sample size indicated in the figure captions. Data were analyzed using either one-way analysis of variance (ANOVA) or two-way ANOVA, followed by Tukey's multiple comparison test for comparison of multiple groups using Prism 7.0e (GraphPad Software). Animal survival was analyzed by the log-rank (Mantel–Cox) test. \* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$ , and \*\*\*\* $P < 0.0001$ .

## Supporting Information

Supporting Information is available from the Wiley Online Library or from the author.

## Acknowledgements

This work was supported in part by National Institutes of Health (NIH) (R01EB022563, R01AI127070, R01CA210273, R01CA223804, R01DK125087, and U01CA210152), The Michigan Translational Research and Commercialization for Life Sciences Hub, and Emerald Foundation.

J.J.M. was supported by The Department of Defense/Congressionally Directed Medical Research Programs Peer Reviewed Cancer Research Program (W81XWH-16-1-0369) and National Science Foundation (NSF) Faculty Early Career Development Program (CAREER) Award (1553831). K.S.P. acknowledges financial support from the University of Michigan Tissue Engineering and Regeneration Training Program (DE007057 from National Institute for Dental and Craniofacial Research). C.L. was supported by a predoctoral fellowship from the Cellular Biotechnology Training Program (T32GM008353) and a Graduate Assistance in Areas of National Need Fellowship awarded to the University of Michigan. Opinions, interpretations, conclusions, and recommendations are those of the authors and are not necessarily endorsed by the Department of Defense. The authors acknowledge the NIH Tetramer Core Facility (contract HHSN272201300006C) for provision of major histocompatibility complex class-I tetramers.

## Conflict of Interest

The authors declare no conflict of interest.

## Keywords

biodegradable nanoparticles, silica nanoparticles, cancer immunotherapies, STING agonists

Received: June 5, 2020

Revised: July 5, 2020

Published online: July 21, 2020

- [1] M. Motwani, S. Pesiridis, K. A. Fitzgerald, *Nat. Rev. Genet.* **2019**, *20*, 657.
- [2] S. R. Woo, M. B. Fuentes, L. Corrales, S. Spranger, M. J. Furdyna, M. Y. Leung, R. Duggan, Y. Wang, G. N. Barber, K. A. Fitzgerald, M. L. Alegre, T. F. Gajewski, *Immunity* **2014**, *41*, 830.
- [3] A. Li, M. Yi, S. Qin, Y. Song, Q. Chu, K. Wu, *J. Hematol. Oncol.* **2019**, *12*, 35.
- [4] S. R. Woo, L. Corrales, T. F. Gajewski, *Trends Immunol.* **2015**, *36*, 250.
- [5] L. Corrales, L. H. Glickman, S. M. McWhirter, D. B. Kanne, K. E. Sivick, G. E. Katibah, S. R. Woo, E. Lemmens, T. Banda, J. J. Leong, K. Metchette, T. W. Dubensky, T. F. Gajewski, *Cell Rep.* **2015**, *11*, 1018.
- [6] S. K. Gadkaree, J. Fu, R. Sen, M. J. Korner, C. Allen, Y. J. Kim, *Head Neck* **2017**, *39*, 1086.
- [7] G. N. Barber, *Nat. Rev. Immunol.* **2015**, *15*, 760.
- [8] T. Su, Y. Zhang, K. Valerie, X. Y. Wang, S. Lin, G. Zhu, *Theranostics* **2019**, *9*, 7759.
- [9] K. E. Sivick, A. L. Desbien, L. H. Glickman, G. L. Reiner, L. Corrales, N. H. Surh, T. E. Hudson, U. T. Vu, B. J. Francica, T. Banda, G. E. Katibah, D. B. Kanne, J. J. Leong, K. Metchette, J. R. Bruml, C. O. Ndubaku, J. M. McKenna, Y. Feng, L. Zheng, S. L. Bender, C. Y. Cho, M. L. Leong, A. van Elsas, T. W. Dubensky, S. M. McWhirter, *Cell Rep.* **2018**, *25*, 3074.
- [10] D. Shae, K. W. Becker, P. Christov, D. S. Yun, A. K. R. Lytton-Jean, S. Sevimli, M. Ascano, M. Kelley, D. B. Johnson, J. M. Balko, J. T. Wilson, *Nat. Nanotechnol.* **2019**, *14*, 269.
- [11] M. C. Hanson, M. P. Crespo, W. Abraham, K. D. Moynihan, G. L. Szeto, S. H. Chen, M. B. Melo, S. Mueller, D. J. Irvine, *J. Clin. Invest.* **2015**, *125*, 2532.
- [12] M. Luo, H. Wang, Z. Wang, H. Cai, Z. Lu, Y. Li, M. Du, G. Huang, C. Wang, X. Chen, M. R. Porembka, J. Lea, A. E. Frankel, Y. X. Fu, Z. J. Chen, J. Gao, *Nat. Nanotechnol.* **2017**, *12*, 648.
- [13] L. Miao, L. Li, Y. Huang, D. Delcassian, J. Chahal, J. Han, Y. Shi, K. Sadtler, W. Gao, J. Lin, J. C. Doloff, R. Langer, D. G. Anderson, *Nat. Biotechnol.* **2019**, *37*, 1174.
- [14] C. Louttit, K. S. Park, J. J. Moon, *Biomaterials* **2019**, *217*, 119287.
- [15] Z. Li, J. C. Barnes, A. Bosoy, J. F. Stoddart, J. I. Zink, *Chem. Soc. Rev.* **2012**, *41*, 2590.
- [16] I. I. Slowing, J. L. Vivero-Escoto, C. W. Wu, V. S. Lin, *Adv. Drug Delivery Rev.* **2008**, *60*, 1278.
- [17] D. Shen, J. Yang, X. Li, L. Zhou, R. Zhang, W. Li, L. Chen, R. Wang, F. Zhang, D. Zhao, *Nano Lett.* **2014**, *14*, 923.
- [18] V. Cauda, A. Schlossbauer, T. Bein, *Microporous Mesoporous Mater.* **2010**, *132*, 60.
- [19] Z. Li, J. C. Barnes, A. Bosoy, J. F. Stoddart, J. I. Zink, *Chem. Soc. Rev.* **2012**, *41*, 2590.
- [20] N. Benne, J. van Duijn, J. Kuiper, W. Jiskoot, B. Slütter, *J. Controlled Release* **2016**, *234*, 124.
- [21] D. Kwon, B. G. Cha, Y. Cho, J. Min, E. B. Park, S. J. Kang, J. Kim, *Nano Lett.* **2017**, *17*, 2747.
- [22] C. Xu, J. Nam, H. Hong, Y. Xu, J. J. Moon, *ACS Nano* **2019**, *13*, 12148.
- [23] Y. Wang, K. Zhou, G. Huang, C. Hensley, X. Huang, X. Ma, T. Zhao, B. D. Sumer, R. J. DeBerardinis, J. Gao, *Nat. Mater.* **2014**, *13*, 204.
- [24] B. J. Francica, A. Ghasemzadeh, A. L. Desbien, D. Theodoros, K. E. Sivick, G. L. Reiner, L. Hix Glickman, A. E. Marciscano, A. B. Sharabi, M. L. Leong, S. M. McWhirter, T. W. Dubensky, D. M. Pardoll, C. G. Drake, *Cancer Immunol. Res.* **2018**, *6*, 422.
- [25] S. K. Sundararaman, D. A. Barbie, *Immunity* **2018**, *49*, 585.
- [26] G. Alter, J. M. Malenfant, M. Altfeld, *J. Immunol. Methods* **2004**, *294*, 15.
- [27] E. Aktas, U. C. Kucuksezer, S. Bilgic, G. Erten, G. Deniz, *Cell Immunol.* **2009**, *254*, 149.
- [28] L. C. Lin, C. Y. Huang, B. Y. Yao, J. C. Lin, A. Agrawal, A. Algaissi, B. H. Peng, Y. H. Liu, P. H. Huang, R. H. Juang, Y. C. Chang, C. T. Tseng, H. W. Chen, C. J. Hu, *Adv. Funct. Mater.* **2019**, *29*, 1807616.
- [29] P. U. Atukorale, S. P. Raghunathan, V. Raguveer, T. J. Moon, C. Zheng, P. A. Bielecki, M. L. Wiese, A. L. Goldberg, G. Covarrubias, C. J. Hoimes, E. Karathanasis, *Cancer Res.* **2019**, *79*, 5394.
- [30] D. R. Wilson, R. Sen, J. C. Sunshine, D. M. Pardoll, J. J. Green, Y. J. Kim, *Nanomedicine* **2018**, *14*, 237.
- [31] A. C. Anselmo, S. Mitragotri, *AAPS J.* **2015**, *17*, 1041.
- [32] J. Fu, D. B. Kanne, M. Leong, L. H. Glickman, S. M. McWhirter, E. Lemmens, K. Metchette, J. J. Leong, P. Lauer, W. Liu, K. E. Sivick, Q. Zeng, K. C. Soares, L. Zheng, D. A. Portnoy, J. J. Woodward, D. M. Pardoll, T. W. Dubensky, Jr., Y. Kim, *Sci. Transl. Med.* **2015**, *7*, 283ra52.
- [33] O. Demaria, A. De Gassart, S. Coso, N. Gesteremann, J. Di Domizio, L. Flatz, O. Gaide, O. Michielin, P. Hwu, T. V. Petrova, F. Martinon, R. L. Modlin, D. E. Speiser, M. Gilliet, *Proc. Natl. Acad. Sci. USA* **2015**, *112*, 15408.
- [34] A. Sallets, S. Robinson, A. Kardosh, R. Levy, *Blood Adv.* **2018**, *2*, 2230.
- [35] A. Ghaffari, N. Peterson, K. Khalaj, N. Vitkin, A. Robinson, J. A. Francis, M. Koti, *Br. J. Cancer* **2018**, *119*, 440.
- [36] J. B. Foote, M. Kok, J. M. Leatherman, T. D. Armstrong, B. C. Marcinkowski, L. S. Ojalvo, D. B. Kanne, E. M. Jaffee, T. W. Dubensky, Jr., L. A. Emens, *Cancer Immunol. Res.* **2017**, *5*, 468.
- [37] L. Milling, Y. Zhang, D. J. Irvine, *Adv. Drug Delivery Rev.* **2017**, *114*, 79.
- [38] L. Scheetz, K. S. Park, Q. Li, P. R. Lowenstein, M. G. Castro, A. Schwendeman, J. J. Moon, *Nat. Biomed. Eng.* **2019**, *3*, 768.
- [39] J. Nam, S. Son, K. S. Park, W. Zou, L. D. Shea, J. J. Moon, *Nat. Rev. Mater.* **2019**, *4*, 398.
- [40] R. S. Riley, C. H. June, R. Langer, M. J. Mitchell, *Nat. Rev. Drug Discovery* **2019**, *18*, 175.
- [41] D. Shen, J. Yang, X. Li, L. Zhou, R. Zhang, W. Li, L. Chen, R. Wang, F. Zhang, D. Zhao, *Nano Lett.* **2014**, *14*, 923.